Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy. By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to develop a predictive biomarker panel capable of differentiating responders from non-responders to targeted therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak jelita grubego z przerzutami.
- •Pacjent przyjmował lek celowany na EGFR lub VEGF.
- •Dostępna próbka krwi sprzed rozpoczęcia leczenia do analizy DNA.
- •Przeprowadzona ocena skuteczności leczenia za pomocą badań obrazowych.
- •Znany status mutacji genów RAS i BRAF.
✗ Disqualifies
- •Zła jakość lub za mało DNA do analizy.
- •Rak innego typu niż gruczolakorak.
- •Inne aktywne choroby nowotworowe (obecne lub w przeszłości).
- •Aktywne choroby zapalne lub autoimmunologiczne, które mogą wpływać na badanie DNA.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
City of Hope Medical Center
Duarte, United States
Trial contact
Ajay Goel, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.